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Objectives: Plasmodium vivax merozoite surface protein 1 (PvMSP1) is the most
intensively studied malaria vaccine candidate. Although high antibody response-
inducing two C-terminal fragments of PvMSP1 (PvMSP1-19 and PvMSP1-42) are
currently being developed as candidate malaria vaccine antigens, their high ge-
netic diversity in various isolates is a major hurdle. The sequence polymorphism of
PvMSP1 has been investigated; however, the humoral immune responses induced
by different portions of this protein have not been evaluated in Korea.
Methods: Two fragments of PvMSP1 were selected for this study: (1) PvMSP1-19,
which is genetically conserved; and (2) PvMSP1-33, which corresponds to a var-
iable portion. For the latter, two representative strains, Sal 1 and Belem, were
included. Thus, three recombinant proteins, PvMSP1-19, PvMSP1-33 Sal 1, and
PvMSP1-33 Belem, were produced in Escherichia coli and then tested by enzyme-
linked immunosorbent assays using sera from 221 patients with vivax malaria.
Results: Of the 221 samples, 198, 142, and 106 samples were seropositive for
PvMSP1-19, PvMSP1-33 Sal 1, and PvMSP1-33 Belem, respectively. Although 100
samples were simultaneously seropositive for antibodies specific to all the re-
combinant proteins, 39 and six samples were respectively seropositive for anti-
bodies specific to MSP1-33 Sal 1 and MSP1-33 Belem. Antibodies specific to
PvMSP1-19 were the most prevalent.
Conclusion: Monitoring seroprevalence is essential for the selection of promising
vaccine candidates as most of the antigenic proteins in P. vivax are highly
polymorphic.his work.
ase Control and Prevention. Published by Elsevier Korea LLC. This is an open access article
reativecommons.org/licenses/by-nc-nd/4.0/).
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Plasmodium vivax is the most prevalent species that
causes malaria in humans [1]. It is endemic in the
tropical and subtropical countries of Africa, the Middle
East, the South Pacific, Central and South America, and
in Asia, including the Republic of Korea (ROK) [2,3]. In
recent years, several reports throughout the world have
linked P. vivax to severe disease and death [4e6]. These
findings associated with the emergence of drug-resistant
strains have increased concerns regarding this species
[7]. Since an effective malaria vaccine capable of
inducing robust and long-lasting protection in naturally
exposed individuals would be an important tool for
malaria control, studies evaluating immune responses
against different P. vivax vaccine candidates are ur-
gently required.
Proteins expressed on the surface of P. vivax mero-
zoites are important candidates for malaria vaccine
development. Among these proteins, merozoite surface
protein 1 (MSP1) is the most intensively studied. MSP1
is synthesized as a high molecular weight precursor
(approximately 200 kDa), which is then processed into
several smaller MSPs [8]. During invasion, the C-ter-
minal 42-kDa fragment (MSP1-42) is further processed
into 33-kDa (MSP1-33) and 19-kDa (MSP1-19) frag-
ments. Only the MSP1-19 fragment remains on the
merozoite surface and is transported into the invaded
erythrocytes [9,10]. The C-terminus of MSP1 reportedly
induces high antibody responses in hosts, and specific
antibodies against this region are known to inhibit
merozoite invasion [11,12]. Although both MSP1-19
and MSP1-42 are being considered as potential vac-
cine candidates, the processing and presentation of these
fragments may be problematic due to the large number
of disulfide linkages in the two epidermal growth factor-
like regions of MSP1-19 [13,14]. In addition, the MSP1-
33 fragment, which is the fragment of MSP1-42 without
MSP1-19, shows an extensive polymorphism in malaria
patient populations [15]. Three representative MSP1
variants of P. vivax (PvMSP1)dBelem, Sal-1, and re-
combinant typesdhave been observed in the ROK
[16,17]. In addition, single-nucleotide polymorphisms
have frequently been observed in P. vivax isolates from
vivax malaria patients [15]. Studies on the MSP1
polymorphism have been performed in the ROK; how-
ever, the distribution of strain-specific antibodies has not
yet been evaluated [18,19]. In this study, we generated
three recombinant proteins of which two correspond to
the polymorphic variants of PvMSP1-33 (PvMSP1-33
Sal 1 and PvMSP1-33 Belem) and the other corresponds
to the conserved PvMSP1-19. We also evaluated anti-
body responses to these proteins in individuals infected
with P. vivax in ROK to determine the frequency and the
magnitude of the humoral response against different P.
vivax vaccine candidate antigens.2. Materials and methods
2.1. Ethics statement
This study was approved by the research ethics
committee of Kyungpook National University (Daegu,
Korea). All the participants signed written informed
consent forms and agreed to provide 5-mL blood
samples.
2.2. Sample collection
The samples were collected at hospitals and health
centers throughout the northern region of the ROK,
where vivax malaria is endemic in the summer season
(June to August). In 2015, 90.4% (619/685) of vivax
malaria cases reported in ROK had occurred in this area.
Venous blood samples with EDTA were obtained from
221 individuals showing classic symptoms of malaria,
who sought treatment at the health facilities mentioned
below. The samples were first diagnosed as vivax ma-
laria using a rapid diagnostic test kit (NanoSign Malaria
P.f/P.v; Bioland, Seoul, Korea) at a hospital or health
center. After blood collection and diagnosis, all the
patients were treated with chloroquine. First of all,
600 mg chloroquine was administered, and then three
more doses of 300 mg chloroquine were administered at
6 hours, 24 hours, and 48 hours after the first dose.
The blood samples were centrifuged at 1,500g for
15 minutes to obtain plasma for further studies. The
plasma samples were transported on ice to a laboratory
in the Department of Parasitology and Tropical Medi-
cine at Kyungpook National University and were stored
at 70C until required. The 221 blood samples from
vivax malaria patients consisted of 140 and 81 samples
collected in 2012 and 2013, respectively. All the sam-
ples were collected from symptomatic vivax malaria
patients who had not been previously infected with P.
vivax. The mean age of the patients at sampling in 2012
and 2013 was 43.2 years and 36.4 years, respectively. Of
all patients from whom samples were collected from in
2012 and 2013, 40.0% (56/140) and 30.9% (25/81) were
from men, respectively. In most samples, the P. vivax
parasite was not observed using microscopy due to low
parasitemia, even though the rapid diagnostic test and
nested-polymerase chain reaction (PCR) were positive.
Samples were also obtained from 30 healthy volunteers
who resided in nonendemic areas (southern parts) of the
ROK and had not traveled to vivax malaria endemic
areas.
2.3. Microscopic examination and nested-PCR
for vivax malaria diagnosis
All the blood samples were examined using micro-
scopic analysis of Giemsa-stained thick and thin blood
films and using nested-PCR, targeting the 18S ribosomal
RNA as described previously [20,21]. Briefly, 5 mL of
extracted DNA was used as the template in a primary
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a template in the second amplification. The cycling
conditions for the primary PCR were as follows: initial
denaturation at 94C for 5 minutes, followed by 25
cycles of denaturation at 94C for 30 seconds, annealing
at 60C for 1 minute, and extension at 72C for 1 min-
ute. The cycling conditions for the second PCR were:
initial denaturation at 92C for 5 minutes, followed by
25 cycles of denaturation at 92C for 20 seconds,
annealing at 52C for 20 seconds, and extension at 78C
for 20 seconds. The final PCR products were detected by
staining with ethidium bromide.
2.4. PvMSP1 cloning
Genomic DNA was extracted from a Korean P. vivax
isolate using the QIAamp DNA blood kit (Qiagen,
Valencia, CA, USA) according to the manufacturer’s
instructions. The extracted DNA was used to amplify the
MSP1-33 Sal 1, MSP1-33 Belem, and MSP1-19 genes.
Oligonucleotide primer sets containing BamHI and
EcoRI restriction enzyme sites were designed based on
the following reference genes: PvMSP1 Sal 1 strain
XM001614792 for PvMSP1-33 Sal 1 and PvMSP1-19,
and PvMSP1 Belem strain AF435594 for PvMSP1-33
Belem. The following oligonucleotide primers were
used: for PvMSP1-19 (450 bp), forward primer 50-
CGTGGATCCAATGAAGTGAAGTCTTCTG-30 and
reverse primer 50-TTCGAATTCAAGCTCCATGCA-
CAGGAG-30; for PvMSP1-33 Sal 1 (854 bp), forward
primer 50-GCGGGATCCGTTAAGGAAGCTTTGCA-
AG-30 and reverse primer 50-CGCGAATTCGCAA-
TAAATTCGTTCTTTTTAC-30; and for PvMSP1-33
Belem (993 bp), forward primer 50-CGTGGATCCA-
TAAGCTACCTGTCCAGTG-30 and reverse primer 50-
CGCGAATTCCATCGATTGGGTCTTTTCAGTAG-
3’. Amplification was performed in 50 mL 1  PCR
buffer (Takara, Tokyo, Japan) containing 2.5 U Taq
polymerase, 2 mL DNA template, 10 pmol of each
primer, and 2mM of each deoxynucleoside triphosphate.
The cycling conditions were as follows: initial dena-
turation at 95C for 5 minutes, followed by 35 cycles of
95C for 30 seconds, 58C for 30 seconds, and 72C for
30 seconds, and a final extension step at 72C for
5 minutes. The PCR product was cloned into the BamHI
and EcoRI restriction enzyme sites of the pGEM-4T-1
vector. The resulting plasmid construct was confirmed
with restriction enzyme digestion and nucleotide
sequencing. PvMSP1-33 Sal 1 and PvMSP1-33 Belem
constructs were selected based on sequencing and Basic
Local Alignment Search Tool search results.
2.5. Recombinant PvMSP1 expression and
purification
PvMSP1-33 Sal 1, PvMSP1-33 Belem, and PvMSP1-
19 were expressed individually as glutathione S-trans-
ferase (GST) fusion proteins in the Escherichia coli
BL21 (DE3) strain (GE Healthcare, Chicago, IL, USA)according to the manufacturer’s instructions. E. coli
cells expressing these proteins were washed three times
with phosphate-buffered saline (PBS), lysed in 1%
Triton X-100-PBS, sonicated, and then centrifuged at
10,000g for 10 minutes at 4C. Soluble GST-fused
rPvMSP1-33 Sal1, rPvMSP1-33 Belem, or rPvMSP1-
19 proteins were purified from the cell lysates with
glutathione-Sepharose 4B beads (GE Healthcare) ac-
cording to the manufacturer’s instructions. After purifi-
cation, the GST tag was subsequently removed from the
GST-fusion proteins using a Thrombin Kit (Novagen,
Darmstadt, Germany).
2.6. Sodium dodecyl sulfate polyacrylamide gel
electrophoresis and Western blotting
The expression of recombinant proteins was verified
using sodium dodecyl sulfate polyacrylamide gel elec-
trophoresis (SDS-PAGE) and Coomassie blue staining,
and the antigenicity of the expressed recombinant pro-
teins was confirmed using Western blot analysis. To
identify the antigenicity of the recombinant proteins, we
applied pooled serum from 30 patients infected with P.
vivax to the Western blot. In addition, 10 patients each
infected with P. vivax classified as MSP1 Sal 1 and
MSP1 Belem in a previous study [18] were used for
another Western blot analysis in order to determine
whether the two antigens, PvMSP1-32 Sal 1 and Belem,
could distinguish the respective sera. The recombinant
proteins were separated by 14% SDS-PAGE and then
electroblotted onto a nitrocellulose membrane [22]. The
membranes were blocked with 5% skimmed milk in
PBS plus 0.05% Tween 20 and then probed with pooled
serum (1:100) as the primary antibody. After the
membrane was washed with PBS plus Tween 20,
horseradish peroxidase-conjugated antihuman immuno-
globulin G (1:2,000; Bethyl Laboratories, Montgomery,
TX, USA) was applied as the secondary antibody.
Finally, the reacted proteins were detected via chem-
iluminescence using enhanced chemiluminescence
Western blotting detection reagents (Amersham Bio-
sciences, Piscataway, NJ, USA).
2.7. Enzyme-linked immunosorbent assay
The optimal concentrations or dilutions of the anti-
gen, serum, enzymeeantibody conjugate, and substrate
solutions were determined through “checkerboard” ti-
trations of each reagent against all other reagents. In-
dividual wells of a microtiter plate (Nunc, Roskilde,
Denmark) were coated overnight at 4C with the puri-
fied rPvMSP1-19, rPvMSP1-33 Sal1, and rPvMSP1-33
Belem proteins (1 mg/mL) dissolved in 0.05M
carbonate-bicarbonate buffer (pH 9.6). The plates were
then blocked with 3% skim milk solution for 1 hour at
37C. After washing with 0.05% Tween 20 in PBS, the
plates were incubated with sera at a dilution of 1:100.
The binding of the antibody was detected via incubation
with horseradish peroxidase-conjugated antihuman
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or antihuman IgG1, IgG2, IgG3 (1:5,000; MyBioSource,
San Diego, CA, USA) and 2,20-asinobis (3-
ethylbenzthiazolne sulfonic acid; Sigma-Aldrich, St.
Louis, MO, USA). The optical density (OD) was
measured at 415 nm using an MTP-500 microplate
reader (Corona Electric, Ibaraki, Japan). The mean OD
values of triplicate enzyme-linked immunosorbent assay
(ELISA) results were then calculated. The ELISA titer
was considered as positive when the OD was  0.08,
 0.1, and  0.17 for rPvMSP1-19, rPvMSP1-33 Sal 1,
and rPvMSP1-33 Belem, respectively. The OD cutoff
values (0.08, 0.1, and 0.17) were calculated by deter-
mining the mean OD for normal sera (sera from 30
healthy people) plus threefold standard deviation.
2.8. Genetic polymorphisms of the PvMSP1
gene
The PvMSP1 sequences in the study samples were
obtained from a previous study wherein the same sam-
ples were classified by the PvMSP1 genotype as
PvMSP1 Sal 1, Belem, or recombinant type [18].
2.9. Statistical analysis
The means and standard deviations were calculated,
and the statistical significance of the differences was
determined by Student t test using JMP Version 8 (SAS
Institute Inc., Cary, NC, USA). Differences in the means
were considered as statistically significant when the p
values were < 0.05.3. Results
3.1. Production of PvMSP1-19, PvMSP1-33 Sal
1, and PvMSP1-33 Belem
Three PvMSP1 proteins, PvMSP1-19, PvMSP1-33
Sal 1, and PvMSP1-33 Belem, were selected for this
study (Figure 1A), with the lengths of the nucleotide
sequences of the respective coding regions being 450 bp,
854 bp, and 993 bp (data not shown). PvMSP1-19,
PvMSP1-33 Sal 1, and PvMSP1-33 Belem were
expressed as soluble GST fusion proteins in E. coli, with
molecular masses of approximately 42 kDa, 57 kDa, and
61 kDa, respectively. Subsequently, 16-kDa, 31-kDa,
and 35-kDa proteins of PvMSP1-19, PvMSP1-33 Sal 1,
and PvMSP1-33 Belem, respectively, were produced
upon GST cleavage by thrombin (Figure 1B).
3.2. Reactivity of PvMSP1-19, PvMSP1-33 Sal
1, and PvMSP1-33 Belem
To evaluate the antigenicity of PvMSP1-19,
PvMSP1-33 Sal 1, and PvMSP1-33 Belem, we per-
formed Western blotting with the three recombinant
proteins and sera from patients with vivax malaria and
healthy individuals. The recombinant proteins reacted
with the sera from the infected patients but not withthose from healthy individuals, indicating that the re-
combinant proteins could be used to detect P. vivax
infection in a serum sample (Figure 1C).
Subsequently, another Western blot analysis was
performed to confirm whether rPvMSP1-33 Sal 1 and
rPvMSP1-33 Belem could differentiate the sera from
patients infected with P. vivax Sal 1 and Belem strains.
Infection with P. vivax Sal 1 and Belem was determined
based on data from our previous study where infection
with these strains was detected by sequencing the
PvMSP1 gene [18]. The results showed that the serum
from patients infected with P. vivax MSP Sal 1 reacted
to rPvMSP1-33 Sal 1 but not to rPvMSP1-33 Belem. In
contrast, rPvMSP1-33 Belem reacted to the serum
collected from a patient infected P. vivax Belem, but not
to rPvMSP1-33 Sal 1 (Figure 1C).
3.3. Prevalence of antibodies specific to
PvMSP1-19, PvMSP1-33 Sal 1, and
PvMSP1-33 Belem
Among the 221 samples from patients with confirmed
vivax malaria, 198 (89.6%), 142 (64.3%), and 106
(48.0%) samples were seropositive for PvMSP1-19,
PvMSP1-33 Sal 1, and PvMSP1-33 Belem, respec-
tively (Table 1). In addition, the levels of PvMSP1-19
antibodies were significantly higher than the levels of
PvMSP1-33 Sal 1 and Belem antibodies (Figure 2).
However, the percentage of samples that were sero-
negative for PvMSP1-33 Sal 1 (35.7%) and PvMSP1-33
Belem (52.0%) was higher than that for PvMSP1-19
(10.4%). Moreover, 100 (45.3%) samples were sero-
positive for antibodies to all three recombinant proteins
(Table 2).4. Discussion
Surveillance studies for the prevalence of antibodies
specific to vaccine candidates must be performed before
selecting a candidate for the development of serodiag-
nostic tools and vaccines, especially since most of the
promising vaccine and serodiagnostic candidates are
highly polymorphic. Therefore, this study investigated
the prevalence of antibodies specific to PvMSP1-19,
PvMSP1-33 Sal 1, and PvMSP1-33 Belem, which are
promising vaccine candidates, in Korean P. vivax
isolates.
In Western blotting analyses, the three recombinant
proteins successfully demonstrated antigenicity. The
antibody response to a Plasmodium antigen depends on
the correct folding of conformational epitopes in the
antigen. Therefore, in order to investigate the prevalence
of antibodies to PvMSP1-19, PvMSP1-33 Sal 1, and
PvMSP1-33 Belem, the recombinant proteins should be
structurally similar to the native proteins. Previously,
recombinant PvMSP1 fragments were used to determine
Figure 1. Diagram and antigenicity evaluation of three recombinant Plasmodium vivax merozoite surface protein 1 (PvMSP1)
proteins: rPvMSP1-19, rPvMSP1-33 Sal 1, and rPvMSP1-33 Belem. (A) A diagram of the three recombinant proteins produced.
(B) SDS-PAGE of rPvMSP1-19, rPvMSP1-33 Sal 1, and rPvMSP1-33 Belem. Successful expression of these recombinant proteins
in Escherichia coli was confirmed using SDS-PAGE and Coomassie blue staining. (C) Western blot analyses of rPvMSP1-19,
rPvMSP1-33 Sal 1, and rPvMSP1-33 Belem. Antigenicity and the ability to differentiate specific antibodies against the three
recombinant proteins were analyzed via Western blotting with sera obtained from patients infected with PvMSP1-Sal 1 (patient
serum-MSP1 Sal 1) and PvMSP1-Belem (patient serum-MSP1 Belem), and sera from healthy individuals (normal serum). Lanes:
M, molecular mass marker; 1, rPvMSP1-Belem; 2, rPvMSP1-Sal 1; 3, rPvMSP1-19. SDS-PAGE Z sodium dodecyl sulfate-
polyacrylamide gel electrophoresis.
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several studies on the prevalence of specific antibodies
to these PvMSP1 fragments have been conducted
[12,24,25]. Therefore, the recombinant proteins gener-
ated in this study, were used to evaluate the antibody
prevalence in patients with vivax malaria from the ROK.
Our ELISA results showed that the levels of
PvMSP1-19 antibodies were significantly higher than
the levels of PvMSP1-33 Sal 1 and Belem antibodies.
This may be caused by the presence of two cysteine-rich
and immunogenic epidermal growth factor-like domains
in PvMSP1-19. Nonetheless, more samples were sero-
negative for PvMSP1-33 Sal 1 and PvMSP1-33 Belem
compared with that for PvMSP1-19, possibly due to aTable 1. Seroprevalence of antibodies specific to Plasmodium v
Sal 1, and PvMSP1-23 Belem in 221 samples from a
PvMSP1-19*
Positive, n (%) 198 (89.6)
Negative, n (%) 23 (10.4)
* p < 0.05 in antibody levels between PvMSP1-19 and PvMSP1-23 Sal 1 orhypervariable region in the PvMSP1-33 fragments. In
addition, approximately 100 patients possessed more
than two types of PvMSP1-specific antibodies to
different strains of PvMSP1, namely PvMSP1 Sal 1 and
Belem. These results are consistent with previous
studies that showed high multiplicities of infection for
P. vivax in Korea [26,27]. However, these studies did
not evaluate whether the high multiplicity of infection,
as determined with nucleotide sequencing, results in the
production of antibodies specific to each strain. In
addition, 39 (17.6%) and six (2.7%) PvMSP1-19-
seropositive serum samples were also seropositive for
PvMSP1-33 Sal 1 and PvMSP1-33 Belem, respectively
(Table 2). In a previous study by Kang et al [15], Koreanivax merozoite surface protein 1 (PvMSP1)-19, PvMSP1-23
Korean population.
PvMSP1-23 Sal 1 PvMSP1-23 Belem
142 (64.3) 106 (48.0)
79 (35.7) 115 (52.0)
PvMSP1-23 Belem.
Figure 2. Levels of antibodies specific to Plasmodium vivax merozoite surface protein 1 (PvMSP1)-19, PvMSP1-23 Sal 1, and
PvMSP1-23 Belem among malaria patients in vivax endemic regions of Korea. * p < 0.05. OD Z optical density.
Table 2. Details of the patterns of seropositivity to Plasmodium vivax merozoite surface protein 1 (PvMSP1)-19, PvMSP1-23
Sal 1, and PvMSP1-23 Belem in 221 P. vivax-infected Korean individuals.
Case 1 Case 2 Case 3 Case 4 Case 5 Case 6 Case 7 Case 8 Total
PvMSP1-19 þ þ þ þ    
PvMSP1-23 Sal 1 þ  þ  þ þ  
PvMSP1-23 Belem þ   þ  þ þ 
No. of individuals,
n (%)
100 (45.3) 53 (24.0) 39 (17.6) 6 (2.7) 3 (1.4) 0 (0) 0 (0) 20 (9.0) 221 (100)
218 S.-D. Dinzouna-Boutamba, et alP. vivax isolates showed high genetic diversity in the
PvMSP1-33 region. In addition, PvMSP1 has been
classified not only as Sal 1 and Belem, but also as re-
combinant and mutant type [28]. This high genetic di-
versity might result in seropositivity for PvMSP1-19 and
seronegativity for PvMSP1-33 Sal 1 and PvMSP1-33
Belem.
PvMSP1-19 is a C-terminal fragment located in a
conserved region of PvMSP1. Current results showed
that PvMSP1-19 is highly antigenic, and that antibodies
specific to PvMSP1-19 are the most prevalent antibodies
in Korean patients with P. vivax. In addition, seropre-
valence studies for specific antibodies to the candidates
of the vaccine and serodiagnostic tools are crucial for
the development of these preventive and diagnostic
strategies.Conflicts of interest
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